Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | AGXT | P21549 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643273 | 0.91 | TAAR1 (0.44) | TAAR1IDO1AGXTMAOBBACE1 | |
| SCHEMBL3645295 | 0.86 | TAAR1 (0.40) | TAAR1IDO1AGXTMAOBBACE1 | |
| SCHEMBL9198674 | 0.85 | TAAR1 (0.42) | TAAR1IDO1AGXTMAOBBACE1 | |
| SCHEMBL722684 | 0.84 | IDO1 (0.56) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL6525763 | 0.84 | IDO1 (0.49) | TAAR1IDO1AGXTMAOB | |
| SCHEMBL22436367 | 0.83 | IDO1 (0.37) | IDO1 | |
| SCHEMBL12093121 | 0.83 | CA12 (0.38) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL1641298 | 0.83 | CA12 (0.35) | — | |
| SCHEMBL15413373 | 0.81 | TAAR1 (0.46) | TAAR1IDO1AGXTMAOBBACE1 | |
| SCHEMBL3698240 | 0.81 | GABRA1 (0.49) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-4225749-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-112423758-A | Adenosine receptor binding compounds | 尼康治疗公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2004096804-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | TAAR1 3163/4885IDO1 3437/4885AGXT 2836/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | TAAR1 3615/4885IDO1 1102/4885AGXT 349/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | TAAR1 3223/4885IDO1 3154/4885AGXT 2912/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | TAAR1 3163/4885IDO1 3437/4885AGXT 2836/4885 |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | TAAR1 1633/4885IDO1 696/4885AGXT 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.